Advances in prostate-specific membrane antigen targeted therapies for prostate cancer.
- Author:
Wei WANG
1
;
Zeng-Nan MO
Author Information
1. Department of Urology, Institute of Urology and Nephrology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, China. wangwei_gxmu@163.com
- Publication Type:Journal Article
- MeSH:
Antigens, Surface;
Genetic Therapy;
Glutamate Carboxypeptidase II;
Humans;
Immunotherapy;
Male;
Prostatic Neoplasms;
drug therapy;
therapy;
Radioimmunotherapy
- From:
National Journal of Andrology
2010;16(6):547-551
- CountryChina
- Language:Chinese
-
Abstract:
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
